Indaptus Therapeutics (NASDAQ:INDP) Stock Rating Lowered by Wall Street Zen

Indaptus Therapeutics (NASDAQ:INDP) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Indaptus Therapeutics Stock Performance

Shares of NASDAQ INDP opened at $2.50 on Friday. The company has a 50 day simple moving average of $2.97 and a two-hundred day simple moving average of $6.35. Indaptus Therapeutics has a fifty-two week low of $1.65 and a fifty-two week high of $47.60. The company has a market capitalization of $4.38 million, a price-to-earnings ratio of -0.08 and a beta of 1.02.

Indaptus Therapeutics (NASDAQ:INDP) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($2.98) EPS for the quarter, topping analysts’ consensus estimates of ($4.17) by $1.19. On average, analysts forecast that Indaptus Therapeutics will post -1.79 earnings per share for the current fiscal year.

Institutional Trading of Indaptus Therapeutics

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC acquired a new stake in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 1.72% of Indaptus Therapeutics as of its most recent SEC filing. 7.06% of the stock is currently owned by institutional investors.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.